Amgen (NSDQ:AMGN) said today that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for its Repatha single monthly injection device. The device is already cleared in Europe for dosing every 2 weeks.
The hands-free device, with prefilled cartridges, delivers 420 milligrams of Repatha (evolocumab) in a single injection. Repatha, a human monoclonal antibody, inhibits a protein which is responsible for blocking the body’s system that naturally eliminates low-density lipoprotein cholesterol.
Get the full story at our sister site, Drug Delivery Business News.
